Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue$104.70M$104.70M+5.2% vs Q2 2018 Net Income$32.73M$32.73M+6.5% vs Q2 2018 EPS Diluted$0.61$0.61+7.0% vs Q2 2018 Operating Income$42,598,000+19.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$28,663,000+358.5% Margins · derivedOperating margin40.7%+4.8 pt vs Q2 2018
Net margin31.3%+0.4 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end